Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality.

ABSTRACT:

Background

More information is needed about the long-term effects of low-dose aspirin (≤160 mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection.

Methods

Using nationwide Swedish registries, we identified all adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and who did not have a history of aspirin use (50,275 patients). Patients who were starting to take low-dose aspirin (14,205 patients) were identified by their first filled prescriptions for 90 or more consecutive doses of aspirin. We constructed a propensity score and applied inverse probability of treatment weighting to balance baseline characteristics between groups.

SUBMITTER: Simon TG 

PROVIDER: S-EPMC7317648 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature